Vice President of Generium Dmitry Kudlai presented the interim results of the development of an innovative vaccine against allergy to pollen of early flowering trees, in particular birch, and cross-food allergy (apple, peach, peanut, soy) at an event in Novosibirsk. The project, implemented jointly by Generium and the Institute of Immunology of the Federal Medical and Biological Agency, has successfully passed the first phase of clinical trials (CT).
The next stage of testing the recombinant drug will be carried out during the period of active birch flowering. The first official results of clinical trials are planned to be presented to the scientific community at the World Immunology Congress in Austria in August 2025. “We will have about a year and a half left for prospective implementation,” he added.
The head of the Federal Medical and Biological Agency Veronika Skvortsova previously said that registration of the drug is expected by the end of 2025, after which it will take about a year and a half to implement it in medical practice. In addition, upon completion of the trials, the drug may be included in the National Immunization Schedule.
